Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

Language: English

You searched for id:"oai:repository.ajou.ac.kr:201003/16590". One record found.

Search Limiters

Last 2 Years | English Only

No search limiters apply to these results.

▼ Search Limiters

1. 이, 성준. Potential Neuroprotection Against Detrimental Effects of Diabetes and Hyperglycemia in Ischemic Stroke.

Degree: 2018, Ajou University

Hyperglycemia and Diabetes mellitus (DM) is a common comorbidity of ischemic stroke, and it is associated with adverse events such as early neurological deterioration (END), infarct growth, hemorrhagic transformation, and increased mortality. In PART I, we evaluated the association between fibrinogen, a prothrombotic protein, and END of diabetic patients with ischemic stroke. In PART II, we evaluated potential effects of admission hyperglycemia on outcomes, infarct growth, and hemorrhagic transformation after endovascular treatment (EVT). In part III, in diabetic rats, we evaluated the ant-ischemic effects of pretreatment with evogliptin, a dipeptidyl peptidase (DPP-4) inhibitor, and metformin, respectively, and combined. PART I: Early Neurological deterioration and fibrinogen We included 3814 ischemic stroke patients within 72 hours of onset. To evaluate the association between fibrinogen and END (National Institutes of Health Stroke Scale [NIHSS] ≥ 2 increase within 1 week of admission), analysis based on propensity score matching between END and non-END population in DM (END, n=261; non-END, n=522) and non-DM populations (END, n=399; non-END, n=798) was performed. Fibrinogen levels were overall higher in the END subgroup compared to non-END subgroup. Only in the DM population were fibrinogen levels an independent predictor for END (fibrinogen levels 300–599 mg/dL, odds ratio: 1.618, 95% confidence interval: 1.037 – 2.525, p=0.034, fibrinogen levels ≥600 mg/dL, 2.575, 1.018 – 6.514, p=0.046; non-DM population, p=0.393). In diabetic patients with acute ischemic stroke, elevated fibrinogen is associated with END dose-dependently. PART II: Adverse effects of hyperglycemia after reperfusion therapy Between January 2011 and May 2016, patients that underwent EVT with pre-procedural and post-procedural diffusion-weighted imaging were identified from a multicenter registry. Normoglycemia was defined as a glucose level ≤110 mg/dL, moderate hyperglycemia as >110 and ≤170 mg/dL, and overt hyperglycemia as >170 mg/dL. Its effects on poor outcomes (3-month modified Rankin Scale score 3–6), infarct growth, and parenchymal hematoma type 2 were analyzed. Of 720 patients encountered, 341 patients were eligible. Glycated hemoglobin levels were higher in overt hyperglycemia group compared to normoglycemia/moderate hyperglycemia group (p<0.001). Moderate hyperglycemia (odds ratio 2.37 [95% confidence interval 1.26–4.45], p=0.007) and overt hyperglycemia (2.84 [1.19–6.81], p=0.019) were associated with poor outcomes. Post-procedural infarct volumes were significantly greater in hyperglycemic patients (padjusted = 0.003). Both findings were confirmed in the total population, and the non-reperfusion subgroup. Only overt hyperglycemia (9.28 [1.66–51.88], p = 0.011) was associated with parenchymal hematoma type 2. This association was confirmed in the total population, and reperfusion subgroup. PART III: Potential neuroprotection of antidiabetic drugs Type 1 diabetes was induced by intraperitoneal injection of streptozotocin in rats aged… Advisors/Committee Members: 대학원 의학과, 201625063, 이, 성준.

Subjects/Keywords: Hyperglycemia; Diabetes mellitus; Fibrinogen; Endovascular therapy; Evogliptin; 고혈당; 당뇨; 동맥내 재관류 치료

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

이, . (2018). Potential Neuroprotection Against Detrimental Effects of Diabetes and Hyperglycemia in Ischemic Stroke. (Thesis). Ajou University. Retrieved from http://repository.ajou.ac.kr/handle/201003/16590 ; http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000027759

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

이, 성준. “Potential Neuroprotection Against Detrimental Effects of Diabetes and Hyperglycemia in Ischemic Stroke.” 2018. Thesis, Ajou University. Accessed February 20, 2019. http://repository.ajou.ac.kr/handle/201003/16590 ; http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000027759.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

이, 성준. “Potential Neuroprotection Against Detrimental Effects of Diabetes and Hyperglycemia in Ischemic Stroke.” 2018. Web. 20 Feb 2019.

Vancouver:

이 . Potential Neuroprotection Against Detrimental Effects of Diabetes and Hyperglycemia in Ischemic Stroke. [Internet] [Thesis]. Ajou University; 2018. [cited 2019 Feb 20]. Available from: http://repository.ajou.ac.kr/handle/201003/16590 ; http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000027759.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

이 . Potential Neuroprotection Against Detrimental Effects of Diabetes and Hyperglycemia in Ischemic Stroke. [Thesis]. Ajou University; 2018. Available from: http://repository.ajou.ac.kr/handle/201003/16590 ; http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000027759

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

.